Post MI Betablockers for Good?

Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration. 

¿Los betabloqueantes son de por vida luego de un infarto?

This study looked into the cardio protection effect of betablockers (BB) after long term follow up in stable patients with no cardiac failure and a history of MI. 

Using the Danish data base, researchers looked at patients undergoing their first MI at admission, receiving an angiogram, prescribed with aspirin and statins at discharge. 

Patients with prior MI, prior BB indication, or counterindication, were excluded. 

Primary end point was cardiovascular death, repeat MI or a combination of both. 

With over 30,000 patients (58% receiving primary PCI, 26% deferred PCI and 16% just and angiogram) it was observed the overwhelming majority of patients (82%) were still on BB after 3 years.


Read also: Can We Discontinue Betablockers after AMI?


When comparing these patients against those who had abandoned treatment (18%) no differences were found in terms of cardiovascular death, repeat MI or their combination. 

Conclusion

This large registry of an entire country after many years has shown BB do not offer additional protection in stable patients with no cardiac failure undergoing MI

ehaa1058_compressed

Original Title: Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.

Reference: Anders Holt et al. European Heart Journal (2021) 42, 907–914 doi:10.1093/eurheartj/ehaa1058.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...